Author

M. Chesi

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 3 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:differential expression· 3 Approach:experimental assay· 3 Organism:mouse· 3 Research Focus:cell type annotation· 2 Research Focus:gene regulatory network inference· 2 Approach:genetic perturbation / CRISPR· 2 Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1

Frequent Co-Authors

A. Policastro· 1 shared A. Rosato· 1 shared A. Rose· 1 shared A. Santoni· 1 shared A. Tosi· 1 shared A. Viale· 1 shared B. Mattorre· 1 shared B. Wildeman· 1 shared

Activity by Year

2021-2024 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 16 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperImmunology

A. Policastro

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

Microbiome Modulation Uncouples Efficacy and Toxicity Induced by Programmed Death-1/Programmed Death-Ligand1 Blockade

L. L. Cogrossi, P. Zordan, M. Grioni, A. Tosi, N. Rizzo, A. Policastro, B. Mattorre, M. Lorenzoni, G. Meregalli, S. Sisti, F. Sanvito, M. Chesi, L. Bergsagel, N. Clementi, A. Rosato, M. Bellone

This study shows that administering Prevotella melaninogenica to mice with multiple myeloma delays disease progression and enhances the efficacy of PD-1/PD-L1 blockade while reducing toxicity.

bioRxiv · May 8, 2024 · PreprintImmunology

The Vk*MYC Mouse Model recapitulates human multiple myeloma evolution and genomic diversity

F. MAURA, D. G. Coffey, C. K. Stein, E. Braggio, B. Ziccheddu, M. E. Sharik, M. Du, Y. T. Alvarado, C.-X. Shi, Y. X. Zhu, E. W. Meermeier, G. J. Morgan, O. Landgren, L. Bersagel, M. Chesi

The paper develops a Vk*MYC mouse model of multiple myeloma that mirrors human disease progression, genomic diversity, and key molecular features.

bioRxiv · Jul 25, 2023 · PreprintCancer Biology

Targeting DNA2 Overcomes Metabolic Reprogramming in Multiple Myeloma

N. Thongon, F. Ma, P. Lockyer, N. Baran, J. Liu, C. Jackson, A. Rose, B. Wildeman, M. Marchesini, V. Marchica, P. Storti, N. Giuliani, I. Ganan-Gomez, V. Adema, Y. Qing, , S. Colla

This study identifies DNA2 as a key factor in mitochondrial metabolism that enables multiple myeloma cells to survive DNA damage, showing that targeting DNA2 overcomes metabolic reprogramming and enhances therapy effectiveness.

bioRxiv · Feb 22, 2023Cancer Biology

Single-cell transcriptional analysis of the immune tumour microenvironment during myeloma disease evolution

D. C. Croucher, L. M. Richards, D. Waller, Z. Li, X. F. Huang, M. Chesi, P. L. Bergsagel, M. Sebag, T. J. Pugh, S. Trudel

This study uses single-cell RNA-sequencing to analyze immune cell changes in myeloma progression and identifies potential therapeutic targets for early intervention.

bioRxiv · Oct 22, 2021 · PreprintCancer Biology